Seriously, Aon, you think weight loss drugs save money?

By AL LEWIS Last month Aon, the major benefits consulting firm, released a “study” claiming: A significant opportunity to reduce healthcare costs for employers and enhance overall workforce health through a comprehensive obesity management program that includes GLP-1 medications. This, of course, is the opposite of what most researchers have shown.  And in the immortal…

Read More

How do drug prices change before loss of exclusivity?

Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and rebates. A paper by Lin et al. (2024) uses 2007-2023 data on drug prices from SSR Health to answer…

Read More

Improving the Patient Journey in Drug Development

[Sponsored] PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar. The post Improving the Patient Journey in Drug Development appeared first on MedCity News.

Read More